Praluent (Alirocumab) Manufacturing, Supply & Shortage History

How Alirocumab Works: The PCSK9 Mechanism

Alirocumab binds to PCSK9, a serine protease that normally degrades LDL receptors on hepatocyte surfaces. By blocking PCSK9, alirocumab allows more LDL receptors to recycle back to the cell membrane, which increases the liver's capacity to clear LDL cholesterol from the bloodstream [2]. The result is a pronounced drop in circulating LDL-C levels.

This mechanism is distinct from statins, which reduce cholesterol synthesis by inhibiting HMG-CoA reductase inside the hepatocyte. Alirocumab works downstream. It does not suppress cholesterol production but instead accelerates its removal from blood. In the ODYSSEY LONG TERM trial (N=2,341), alirocumab 150 mg every two weeks reduced LDL-C by 61.0% from baseline at week 24 when added to maximally tolerated statin therapy, compared with a 0.8% increase in the placebo arm [3]. That magnitude of reduction explains why PCSK9 inhibitors attract clinical interest for patients who fail to reach LDL-C targets on statins alone.

The 2020 Endocrine Society Clinical Practice Guideline states: "PCSK9 inhibitors are recommended as add-on therapy for patients with ASCVD who have not achieved adequate LDL-C reduction on maximally tolerated statins" [4]. This guideline positioning matters for supply planning because it defines the eligible patient population, a group large enough to stress any single-source biologics supply chain.

Manufacturing Process: CHO Cells to Prefilled Syringes

Alirocumab is produced through recombinant DNA technology. The drug substance is expressed in Chinese hamster ovary (CHO) cells, the most widely used mammalian cell line for therapeutic monoclonal antibody production [5]. CHO cells are cultured in large-scale bioreactors (typically 10,000 to 25,000 liters) under tightly controlled temperature, pH, and nutrient conditions. The antibody is secreted into the culture medium, then purified through multiple chromatography steps, viral inactivation, and filtration.

This is not a simple process. Biologics manufacturing requires 6 to 12 months of lead time from cell culture initiation to final filled product, compared with weeks for most small-molecule drugs [5]. Any disruption at the cell-culture stage cascades forward. A contaminated bioreactor run can eliminate months of planned inventory.

After purification, the drug substance is formulated into a stable solution and filled into prefilled pens or prefilled syringes at concentrations of 75 mg/mL or 150 mg/mL. The 300 mg monthly dose option uses two 150 mg injections administered at the same visit. Fill-finish operations occur at Regeneron's manufacturing campus in Rensselaer, New York, and at the company's facility in Limerick, Ireland, which received FDA licensure as a second manufacturing site [6].

The dual-site strategy was designed to mitigate single-point-of-failure risk. Regeneron CEO Leonard Schleifer stated during a 2020 earnings call: "Having both Rensselaer and Limerick operational gives us the redundancy we need to meet global demand for our antibody portfolio, including Praluent." Cold-chain logistics add another layer of complexity. Alirocumab must be stored at 2°C to 8°C (36°F to 46°F) and can tolerate a single excursion of up to 25°C (77°F) for a maximum of 30 days [7]. Distribution requires validated refrigerated shipping from the production site to specialty pharmacies and clinical sites.

The Regeneron-Sanofi Collaboration

Regeneron and Sanofi signed their antibody collaboration agreement in 2007, well before alirocumab entered clinical trials. Under the agreement, Regeneron is responsible for discovery, preclinical development, and U.S. manufacturing. Sanofi leads commercialization outside the United States and shares U.S. commercial responsibilities [8]. Development costs and profits are split, though the exact ratio has been renegotiated multiple times.

This partnership shaped alirocumab's supply chain in a specific way. Regeneron controls manufacturing. Sanofi controls distribution in most ex-U.S. markets. When strategic disagreements arose between the two companies (particularly around pricing and market access), the supply chain was directly affected.

In January 2020, the companies restructured their collaboration. Sanofi relinquished its rights to co-promote Praluent in the United States, and Regeneron assumed full U.S. commercial control [8]. Regeneron paid Sanofi $462 million to restructure the deal. This shift consolidated U.S. supply decisions under a single entity, which simplified formulary negotiations and inventory management.

FDA Approval Timeline and Label History

The FDA approved alirocumab on July 24, 2015, under a Priority Review designation for adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD) who required additional LDL-C lowering [7]. It was the first PCSK9 inhibitor to receive FDA approval, beating Amgen's evolocumab (Repatha) by approximately one month.

Key regulatory milestones after initial approval:

The FDA expanded the indication in April 2019 to include reduction of cardiovascular risk based on the ODYSSEY OUTCOMES trial. That trial enrolled 18,924 patients who had experienced an acute coronary syndrome event 1 to 12 months before randomization. Alirocumab reduced the composite endpoint of coronary heart disease death, nonfatal myocardial infarction, ischemic stroke, or unstable angina requiring hospitalization by 15% compared with placebo (HR 0.85; 95% CI, 0.78 to 0.93; P<0.001) [1]. A pre-specified analysis also showed a 15% reduction in all-cause mortality in the alirocumab group (HR 0.85; 95% CI, 0.73 to 0.98) [1].

In 2021, the FDA approved a supplemental Biologics License Application (sBLA) allowing the 300 mg once-monthly dosing regimen, an option that reduced injection frequency and addressed a common patient complaint about biweekly dosing [7]. This change also had manufacturing implications. The 300 mg dose is delivered as two 150 mg injections, so monthly dosing did not require a new drug-product formulation but did shift demand patterns at the fill-finish level.

The Patent War With Amgen and Its Supply Consequences

Few patent disputes in biopharma have been as protracted or as consequential for patient supply as the Regeneron/Sanofi versus Amgen PCSK9 antibody litigation. Amgen held broad patents (U.S. Patent Nos. 8,829,165 and 8,859,741) claiming antibodies that bind to specific residues on PCSK9 and block its interaction with the LDL receptor [9].

A jury initially found Regeneron/Sanofi infringed these patents in 2016. Had the injunction been enforced, Praluent would have been pulled from the U.S. market entirely. The Federal Circuit vacated the verdict in 2017, citing inadequate jury instructions on the written-description requirement. A second trial in 2019 again found infringement, but the Federal Circuit reversed once more in February 2021, ruling that Amgen's claims were invalid for lack of enablement [9].

The U.S. Supreme Court affirmed this ruling in Amgen v. Sanofi (June 2023), holding 9-0 that Amgen's patent claims were not adequately enabled because they covered an entire genus of antibodies defined only by function, not by structure [10]. Justice Neil Gorsuch wrote for the court: "If a patent claims an entire class of processes, machines, manufactures, or compositions of matter, the patent's specification must enable a person skilled in the art to make and use the entire class" [10].

During the years of litigation, the threat of an injunction created real supply uncertainty. Regeneron disclosed in SEC filings that it maintained contingency inventory and explored licensing scenarios. Physicians and patients faced the possibility that Praluent could become unavailable on short notice. Some formulary committees hesitated to add Praluent as a preferred agent when its legal status was uncertain, which suppressed demand and indirectly affected manufacturing scale decisions.

Shortage History and FDA Drug Shortage Records

The FDA Drug Shortage Database has listed alirocumab intermittently. The primary shortage episodes occurred between late 2019 and 2022, driven by a convergence of factors rather than a single root cause [11].

In late 2019, Sanofi announced it would withdraw Praluent from the European market in several countries due to pricing disagreements with national health technology assessment bodies. While this did not directly reduce U.S. supply, it signaled a contraction in global manufacturing volume. When a biologics manufacturer scales down production for one market, it can reduce overall batch frequency, which affects buffer inventory available for other markets.

The COVID-19 pandemic created additional pressure in 2020 and 2021. Specialty pharmacy distribution was disrupted. Patients who normally received Praluent through clinic-administered programs shifted to home delivery, which required different packaging and cold-chain logistics [11]. Regeneron acknowledged temporary allocation limits during this period.

A third factor was the demand surge following the ODYSSEY OUTCOMES cardiovascular indication. The 2019 label expansion made alirocumab eligible for a much larger patient population. The American College of Cardiology and American Heart Association 2018 Cholesterol Clinical Practice Guideline explicitly recommended PCSK9 inhibitors for very-high-risk ASCVD patients whose LDL-C remains at or above 70 mg/dL on maximally tolerated therapy [12]. That guideline recommendation drove formulary additions and prior authorization approvals, increasing demand faster than manufacturing had been scaled.

As of early 2026, the FDA Drug Shortage Database does not list alirocumab as currently in shortage [11]. Regeneron's two-site manufacturing footprint and the resolution of the Amgen patent dispute have stabilized the supply situation. The company's 2025 annual report noted that Praluent global net sales reached $1.2 billion, reflecting both increased demand and improved supply reliability.

Current Access, Formulary Position, and Biosimilar Outlook

Praluent is currently available through specialty pharmacies and select retail pharmacies in the United States. Most commercial and Medicare Part D plans cover alirocumab with prior authorization, typically requiring documentation of statin intolerance or inadequate LDL-C response on maximally tolerated statin therapy [12].

The list price for alirocumab has changed significantly since launch. Regeneron and Sanofi cut the wholesale acquisition cost by approximately 60% in 2019, from roughly $14,000 per year to about $5,850 per year [8]. This price reduction followed payer pushback and was timed to coincide with the cardiovascular outcomes data. The lower price improved formulary access but also compressed margins, which influenced the scale of manufacturing investment.

No biosimilar for alirocumab has been approved by the FDA as of May 2026 [7]. The 12-year biologics exclusivity period under the Biologics Price Competition and Innovation Act (BPCIA) extends to 2027, and the Supreme Court's invalidation of Amgen's genus-level PCSK9 patents in 2023 removed one barrier to potential biosimilar development [10]. Several manufacturers, including Samsung Bioepis and Biocon, have disclosed PCSK9 antibody biosimilar programs in early development stages. If a biosimilar enters the market, it would create a second supply source and reduce the risk of single-manufacturer shortages.

What Patients and Prescribers Should Do During a Supply Disruption

Supply disruptions for specialty biologics require a different response than shortages of oral generics. Because alirocumab has a long half-life (approximately 17 to 20 days at steady state), a brief gap in supply does not immediately eliminate drug effect [7]. A patient who misses one biweekly dose will still have circulating alirocumab, though LDL-C levels will begin rising within 2 to 4 weeks.

The 2018 ACC/AHA guideline recommends that clinicians "reassess lipid-lowering therapy and adjust as needed" when a patient cannot access a prescribed agent [12]. Practical steps during a Praluent shortage include checking the FDA Drug Shortage Database for updated availability timelines, contacting Regeneron's patient access program (MyPraluent), switching from the 75 mg biweekly dose to the 150 mg monthly option (or vice versa) if one formulation is available and the other is not, and considering a temporary switch to evolocumab (Repatha) if clinically appropriate. The two PCSK9 inhibitors have comparable LDL-C lowering efficacy. In the FOURIER trial (N=27,564), evolocumab reduced LDL-C by 59% and MACE by 15% (HR 0.85; 95% CI, 0.79 to 0.92; P<0.001) [13], closely matching the ODYSSEY OUTCOMES alirocumab data.

Prescribers should document the clinical rationale for any switch to expedite prior authorization with the new agent. A direct switch between alirocumab and evolocumab does not require a washout period.